In total, 2% of all 14 193 screened participants had undetected T2D and 7% GMD. This figure would potentially be 4.6% (T2D), respectively 15% (GMD) if all with a FINDRISC>12 attend the OGTT. Thus, we found the FINDRISC to be a useful tool to identify people with GMD. This article is protected by copyright. All rights reserved.

Background: The objective of the demonstration project for type 2 diabetes prevention in the Barranquilla and Juan Mina (DEMOJUAN) study was to investigate the extent to which it is possible to reach normal glucose metabolism with early lifestyle interventions in people at high risk of type 2 diabetes (prediabetes), compared with those who receive standard usual care. Methods: DEMOJUAN was a randomized controlled trial conducted in Juan Mina and Barranquilla, Northern Colombia. Eligible participants were randomized into one of three groups (control group, initial nutritional intervention, and initial physical activity intervention). The duration of the intervention was 24 months. The main study outcome in the present analysis was reversion to normoglycemia. Relative risks and their corresponding 95% confidence intervals were calculated for reversal to normoglycemia and T2D incidence. Results: There was no statistically significant association between the intervention groups and reversion to normoglycemia. The relative risk of reversion to normoglycemia was 0.88 (95% CI 0.70–1.12) for the initial nutritional intervention group participants and 0.95 (95% CI 0.75–1.20) for the initial physical activity intervention group participants. Conclusions: Our study did not find any statistically significant differences in reversion to normoglycemia or the development of type 2 diabetes between the intervention groups and the control group in this population.

Type 2 diabetes (T2D) imposes a heavy public health burden in both developed and developing countries. It is necessary to understand the effect of T2D in different settings and population groups. This report aimed to present baseline characteristics of study participants in the demonstration area for the “Type 2 Diabetes Prevention in Barranquilla and Juan Mina” (DEMOJUAN) project after randomization and to compare their fasting and 2-hour glucose levels according to lifestyle and T2D risk factor levels.The DEMOJUAN project is a randomized controlled field trial. Study participants were recruited from study sites using population-wide screening using the Finnish Diabetes Risk Score (FINDRISC) questionnaire. All volunteers with FINDRISC of ≥13 points were invited to undergo an oral glucose tolerance test (OGTT). Participant inclusion criteria for the upcoming field trial were either FINDRISC of ≥13 points and 2-hour post-challenge glucose level of 7.0 to 11.0 mmol/L or FINDRISC of ≥13 points and fasting plasma glucose level of 6.1 to 6.9 mmol/L. Lifestyle habits and risk factors for T2D were assessed by trained interviewers using a validated questionnaire.Among the 14,193 participants who completed the FINDRISC questionnaire, 35% (n = 4915) had a FINDRISC score of ≥13 points and 47% (n = 2306) agreed to undergo the OGTT. Approximately, 33% (n = 772) of participants underwent the OGTT and met the entry criteria; these participants were randomized into 3 groups. There were no statistically significant differences found in anthropometric or lifestyle risk factors, distribution of the glucose metabolism categories, or other diabetes risk factors between the 3 groups (P > .05). Women with a past history of hyperglycaemia had significantly higher fasting glucose levels than those without previous hyperglycaemia (103 vs 99 mg/dL; P < .05).Lifestyle habits and risk factors were evenly distributed among the 3 study groups. No differences were found in fasting or 2-hour glucose levels among different lifestyle or risk factor categories with the exception of body mass index, past history of hyperglycaemia, and age of ≥64 years in women.Trial registration: NCT01296100 (2/12/2011; Clinical trials.gov).

S77ObjectiveS: Characterize baseline clinical and patient-centric characteristics of type 2 diabetes mellitus (T2DM) patients who met criteria for an online patient engagement tool. MethOdS: This study analyzed pooled baseline data from T2DM patients identified for a prospective evaluation of an online patient engagement tool at two sites; Henry Ford Health System and Northwell Health. Patients were eligible if they were ≥ 18 years of age, diagnosed with T2DM, and had a baseline Patient Activation Measure (PAM) level 2 'Becoming Aware' or 3 'Taking Action'. Clinical assessments and patient reported outcomes (PROs) were collected online and described using summary statistics. ReSultS: 662 participants consented and provided PAM data, with 15.9% and 48.8% at PAM levels 2 and 3, respectively. Patients at levels 1 (5.4%) and 4 (29.9%) were ineligible. 363 patients met all eligibility criteria for this analysis. Participants were primarily white (58.4%), females (59.0%) with a mean age of 57.4 (SD: 11.1) years and PAM level of 3 (76.6%). Mean time since diagnosis of T2DM was 10.4 (SD: 8.3) years. The most common comorbidities were hypertension and hypercholesterolemia/hyperlipidemia (20.7% each). 39.4% of patients had hemoglobin A1c ≥ 8.0% (mean: 8.0%, SD: 1.8) and mean body mass index (BMI) was 36.3 (SD: 7.4) kg/m2, with 80.2% being considered obese (BMI ≥ 30 kg/m2). Mean physical and mental component summary scores from the Short Form 12 were 40.9 (SD: 16.1) and 44.9 (SD: 17.1), respectively, indicating impaired functioning in each dimension. Mean Diabetes Distress Scale scores indicated moderate regimen-related distress (3.1, SD: 1.2) and emotional burden (2.7, SD: 1.2), suggesting clinical attention is necessary. cOncluSiOnS: Clinical measurements and PROs in our population of T2DM patients with PAM level 2/3 suggest a need for clinical and lifestyle intervention. Further research is needed to confirm appropriate clinical intervention and the potential effectiveness of targeted patient engagement tools.